104 related articles for article (PubMed ID: 30269037)
1. Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon.
de Carvalho DC; Wanderley AV; Dos Santos AMR; Fernandes MR; Cohen Lima de Castro AN; Leitão LPC; de Carvalho JAN; de Souza TP; Khayat AS; Dos Santos SEB; de Assumpção PP; Dos Santos NPC
Leuk Res; 2018 Nov; 74():10-13. PubMed ID: 30269037
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
3. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
4. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
5. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy.
Eldem İ; Yavuz D; Cumaoğullari Ö; İleri T; Ünal İnce E; Ertem M; Doğanay Erdoğan B; Bindak R; Özdağ H; Şatiroğlu-Tufan NL; Uysal LZ
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e289-e294. PubMed ID: 29683944
[TBL] [Abstract][Full Text] [Related]
6. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
Treenert A; Areepium N; Tanasanvimon S
Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
[TBL] [Abstract][Full Text] [Related]
7. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S; Marable M; Huang RS
Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
[TBL] [Abstract][Full Text] [Related]
9. Influence of Genetic Variations in miRNA and Genes Encoding Proteins in the miRNA Synthesis Complex on Toxicity of the Treatment of Pediatric B-Cell ALL in the Brazilian Amazon.
da Silva Menezes E; de Moraes FCA; de Nazaré Cohen-Paes A; Wanderley AV; Pereira EEB; Pastana LF; Modesto AAC; de Assumpção PP; Burbano RMR; Dos Santos SEB; Dos Santos NPC; Fernandes MR
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901860
[TBL] [Abstract][Full Text] [Related]
10. Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia.
Suzuki R; Fukushima H; Noguchi E; Tsuchida M; Kiyokawa N; Koike K; Ma E; Takahashi H; Kobayashi C; Nakajima-Yamaguchi R; Sakai A; Saito M; Iwabuchi A; Kato K; Nakao T; Yoshimi A; Sumazaki R; Fukushima T
Pediatr Int; 2015 Aug; 57(4):572-7. PubMed ID: 25939871
[TBL] [Abstract][Full Text] [Related]
11. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
Sortica Vde A; Ojopi EB; Genro JP; Callegari-Jacques S; Ribeiro-Dos-Santos A; de Moraes MO; Romano-Silva MA; Pena SD; Suarez-Kurtz G; Hutz MH
Basic Clin Pharmacol Toxicol; 2012 May; 110(5):460-8. PubMed ID: 22136368
[TBL] [Abstract][Full Text] [Related]
12. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
13. Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.
Sharifi MJ; Bahoush G; Zaker F; Ansari S; Rafsanjani KA; Sharafi H
Pediatr Hematol Oncol; 2014 Mar; 31(2):169-77. PubMed ID: 24552501
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
15. Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in Amazonian native Americans population.
de Carvalho DC; Wanderley AV; Dos Santos AMR; Moreira FC; de Sá RBA; Fernandes MR; Modesto AAC; de Souza TP; Cohen-Paes A; Leitão LPC; Rodrigues JCG; da Silva ALDC; Guerreiro JF; Santos S; Khayat AS; de Assumpção PP; Dos Santos NPC
Sci Rep; 2020 Jun; 10(1):10292. PubMed ID: 32581388
[TBL] [Abstract][Full Text] [Related]
16. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.
Maxwell RR; Cole PD
Curr Hematol Malig Rep; 2017 Jun; 12(3):176-186. PubMed ID: 28317081
[TBL] [Abstract][Full Text] [Related]
18. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
[TBL] [Abstract][Full Text] [Related]
19. Influence of variants of the
de Souza TP; de Carvalho DC; Wanderley AV; Fernandes SM; Rodrigues JCG; Cohen-Paes A; Fernandes MR; Mello Junior FAR; Pastana LF; Vinagre LWMS; Silva ALDC; de Assumpção PP; Santos S; Khayat AS; Dos Santos NPC
Am J Transl Res; 2020; 12(12):8216-8224. PubMed ID: 33437394
[TBL] [Abstract][Full Text] [Related]
20. An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure.
Vandell AG; Lee J; Shi M; Rubets I; Brown KS; Walker JR
Pharmacogenomics J; 2018 Jan; 18(1):153-159. PubMed ID: 27897269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
